RICO claims brought against GlaxoSmithKline for its marketing of the diabetes drug Avandia have cleared a hurdle in federal court in Philadelphia.
U.S. District Judge Cynthia M. Rufe of the Eastern District of Pennsylvania held that the claims brought as a potential class action by the benefit funds of three labor unions under the Racketeer Influenced and Corrupt Organizations Act can proceed against the pharmaceutical giant. She dismissed claims for unjust enrichment.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
